📊 CYCN Key Takeaways
Is Cyclerion Therapeutics, Inc. (CYCN) a Good Investment?
Cyclerion is a pre-revenue pharmaceutical company with severe operational losses and negative cash burn. With only $1.0M in revenue against $4.1M operating losses, the company is burning cash at an unsustainable rate with just $4.6M cash remaining and no clear path to profitability.
Cyclerion Therapeutics shows very weak fundamentals, with minimal revenue, deeply negative operating and net margins, and negative free cash flow that indicates the business is not self-sustaining. While the balance sheet is currently supported by strong liquidity and no meaningful leverage, the small cash base relative to ongoing losses creates substantial funding and dilution risk unless operating performance improves materially.
Why Buy Cyclerion Therapeutics, Inc. Stock? CYCN Key Strengths
- Strong liquidity position with 5.78x current ratio providing near-term survival runway
- Zero debt burden eliminates financial leverage risk
- Meaningful cash reserves of $4.6M relative to asset base
- Strong near-term liquidity with current and quick ratios of 5.78x
- No meaningful debt burden, reducing balance-sheet stress
- Positive stockholders' equity of $9.54M provides some financial cushion
CYCN Stock Risks: Cyclerion Therapeutics, Inc. Investment Risks
- Severe cash burn of $1.7M quarterly with operating losses of $4.1M indicates runway of less than 3 quarters without additional funding
- Revenue of $1.0M is negligible for a biopharmaceutical company, suggesting failed commercialization or non-existent product sales
- Negative operating margin of -394% and net margin of -260% indicate fundamental business model failure
- Zero insider transactions in 90 days suggests management confidence issues or restricted trading windows
- Pre-commercial or failed-commercial stage company with no visibility to positive cash flow
- Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%
- Negative operating cash flow and free cash flow indicate continuing cash burn
- Low revenue base of $1.05M suggests limited commercial scale and poor growth quality
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash runway before capital raise necessity
- Revenue growth trajectory and clinical development milestones
- Operating expense reduction and path to cash flow breakeven
- Quarterly operating cash burn relative to cash and equivalents
- Revenue growth and improvement in operating loss margin
Cyclerion Therapeutics, Inc. (CYCN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.78x current ratio provides a solid financial cushion.
CYCN Profit Margin, ROE & Profitability Analysis
CYCN vs Healthcare Sector: How Cyclerion Therapeutics, Inc. Compares
How Cyclerion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cyclerion Therapeutics, Inc. Stock Overvalued? CYCN Valuation Analysis 2026
Based on fundamental analysis, Cyclerion Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cyclerion Therapeutics, Inc. Balance Sheet: CYCN Debt, Cash & Liquidity
CYCN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cyclerion Therapeutics, Inc.'s revenue has declined by 47% over the 5-year period, indicating business contraction. The most recent EPS of $-1.21 indicates the company is currently unprofitable.
CYCN Revenue Growth, EPS Growth & YoY Performance
CYCN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $194.0K | -$324.0K | $-0.29 |
| Q2 2025 | N/A | -$324.0K | $-0.11 |
| Q1 2025 | N/A | -$1.4M | $-0.56 |
| Q3 2024 | N/A | -$723.0K | $-0.29 |
| Q3 2023 | N/A | -$3.6M | $-1.55 |
| Q2 2023 | N/A | -$4.2M | $-1.83 |
| Q1 2023 | N/A | -$7.0M | $-0.16 |
| Q3 2022 | N/A | -$10.5M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cyclerion Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
CYCN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYCN
What is the AI rating for CYCN?
Cyclerion Therapeutics, Inc. (CYCN) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 90% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYCN's key strengths?
Claude: Strong liquidity position with 5.78x current ratio providing near-term survival runway. Zero debt burden eliminates financial leverage risk. ChatGPT: Strong near-term liquidity with current and quick ratios of 5.78x. No meaningful debt burden, reducing balance-sheet stress.
What are the risks of investing in CYCN?
Claude: Severe cash burn of $1.7M quarterly with operating losses of $4.1M indicates runway of less than 3 quarters without additional funding. Revenue of $1.0M is negligible for a biopharmaceutical company, suggesting failed commercialization or non-existent product sales. ChatGPT: Extremely weak profitability, with operating margin of -394.2% and net margin of -260.2%. Negative operating cash flow and free cash flow indicate continuing cash burn.
What is CYCN's revenue and growth?
Cyclerion Therapeutics, Inc. reported revenue of $1.0M.
Does CYCN pay dividends?
Cyclerion Therapeutics, Inc. does not currently pay dividends.
Where can I find CYCN SEC filings?
Official SEC filings for Cyclerion Therapeutics, Inc. (CIK: 0001755237) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYCN's EPS?
Cyclerion Therapeutics, Inc. has a diluted EPS of $-0.92.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CYCN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cyclerion Therapeutics, Inc. has a STRONG SELL rating with 90% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CYCN stock overvalued or undervalued?
Valuation metrics for CYCN: ROE of -28.6% (sector avg: 15%), net margin of -260.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CYCN stock in 2026?
Our dual AI analysis gives Cyclerion Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CYCN's free cash flow?
Cyclerion Therapeutics, Inc.'s operating cash flow is $-1.7M, with capital expenditures of $0.0. FCF margin is -165.4%.
How does CYCN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -260.2% (avg: 12%), ROE -28.6% (avg: 15%), current ratio 5.78 (avg: 2).